University of Pennsylvania School of Medicine and AstraZeneca Working Together to Find New Therapies for Alzheimer's Disease.PHILADELPHIA, March 18 /PRNewswire-USNewswire/ -- The University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli.
Address: Philadelphia, PA, USA. and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.
Initially, the collaboration between Penn Medicine and AstraZeneca scientists will focus on generating new Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. (AD) drug candidates for the clinical development pipeline.
In AD, the formation of amyloid amyloid /am·y·loid/ (am´i-loid)
1. starchlike; amylaceous.
2. the pathologic, extracellular, waxy, amorphous substance deposited in amyloidosis, being composed of fibrils in bundles or in a meshwork of polypeptide plaques and neurofibrillary tangles are thought to contribute to the destruction of nerve cells in the brain, leading to subsequent symptoms of the disease. In this collaboration, researchers will focus on the protein tau, which is the key component of tangles in AD.
Penn Medicine's Center for Neurodegenerative Disease Neurodegenerative disease
A disease in which the nervous system progressively and irreversibly deteriorates.
Mentioned in: Amnesia Research (CNDR CNDR Conductor (railroads)
CNDR Consiliul National al Dizabilitatii din Romania (Romanian) ) will provide rapid access to unique state-of-the-art drug compound screening assays and knowledge of the biology of tau - first characterized for its role in dementias by Penn Medicine's Virginia M.-Y. Lee, PhD, MBA, director of CNDR, and John Trojanowski, MD, PhD, director of the Institute on Aging. AstraZeneca scientists will supply basic research with access to the technologies and skills required to discover and develop new drug molecules.
The agreement allows the parties to work closely together in drug discovery and development, and contains potential royalties and milestone payments linked to successful clinical development and eventual world-wide marketing of tau targeted therapies for Alzheimer's disease. AstraZeneca has exclusive access to compound IP and study data for any commercial purposes from research performed under this agreement.
"We are excited about the collaborative drug discovery relationship that CNDR has formed with AstraZeneca, as it builds on the exceptional translational research strengths of the Penn CNDR team in elucidating mechanisms of tau-mediated neurodegeneration in AD," said Dr. Lee, who along with Dr. Trojanowski and Kurt Brunden, PhD, Director of CNDR Drug Discovery, will lead the CNDR component of this new alliance at Penn. "This collaborative research agreement strongly complements both entities' AD drug discovery programs and expands opportunities for developing disease-modifying AD therapies."
No treatment is available to slow or stop the deterioration of brain cells in Alzheimer's disease. Currently there are an estimated 15-20 million people worldwide with AD; 5.3 million Americans have AD. With the aging population worldwide, this figure is set to increase to more than 50 million people by 2050. Alzheimer's disease is the seventh leading cause of death in America; Alzheimer's disease deaths increased 46.1 percent from 2000-2006, while other selected causes of death decreased.
"This agreement offers the hope of accelerating the pace of drug discovery, particularly important given the global burden of AD," added Michael Cleare, PhD, Associate Vice-Provost for Research & Executive Director of the Center for Technology Transfer at Penn. "We believe that joint development relationships of this type will become an increasingly important part of our mission, to make research available for the benefit and betterment of society."
"Finding new therapies that affect tau-mediated neurodegeneration in AD is one key to AstraZeneca's strategy for fighting this disease. We are pleased to be part of such an innovative collaboration, marrying the world-leading disease understanding of Penn's CNDR to the drug discovery experience of AstraZeneca," Johan Lund, Vice President of Discovery Research Area CNS See Continuous net settlement.
See continuous net settlement (CNS). & Pain Control at AstraZeneca in Sodertalje, Sweden.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the University of Pennsylvania School of Medicine The University of Pennsylvania's School of Medicine, presently located in the University City section of Philadelphia, Pennsylvania, was the United States's first school of medicine, founded at the College of Philadelphia, as the University was then called. (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System The University of Pennsylvania Health System is a diverse research and clinical care organization in Philadelphia, Pennsylvania that operates under the direction and auspices of the University of Pennsylvania, its umbrella organization Penn Medicine and the University of , which together form a $3.6 billion enterprise.
Penn's School of Medicine is currently ranked #3 in U.S. News & World Report's survey of research-oriented medical schools, and is consistently among the nation's top recipients of funding from the National Institutes of Health, with $367.2 million awarded in the 2008 fiscal year.
SOURCE Penn Medicine